vs
Side-by-side financial comparison of American Express (AXP) and Johnson & Johnson (JNJ). Click either name above to swap in a different company.
Johnson & Johnson is the larger business by last-quarter revenue ($24.6B vs $18.9B, roughly 1.3× American Express). Johnson & Johnson runs the higher net margin — 20.8% vs 15.7%, a 5.1% gap on every dollar of revenue. On growth, American Express posted the faster year-over-year revenue change (11.4% vs 9.1%). Over the past eight quarters, American Express's revenue compounded faster (38.8% CAGR vs 7.2%).
American Express Company, together with its subsidiaries, provides charge and credit payment card products, and travel-related services worldwide. The company operates through three segments: Global Consumer Services Group, Global Commercial Services, and Global Merchant and Network Services. Its products and services include payment and financing products; network services; accounts payable expense management products and services; and travel and lifestyle services. The company's products an...
Johnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange. Its common stock is a component of the Dow Jones Industrial Average, and the company is ranked No. 48 on the 2025 Fortune 500 list of the largest United States corporations. In 2025, the company was ranked 42th in the Forbes Global 2000.
AXP vs JNJ — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.9B | $24.6B |
| Net Profit | $3.0B | $5.1B |
| Gross Margin | — | 67.6% |
| Operating Margin | — | 20.2% |
| Net Margin | 15.7% | 20.8% |
| Revenue YoY | 11.4% | 9.1% |
| Net Profit YoY | 15.0% | 49.1% |
| EPS (diluted) | $4.28 | $2.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $18.9B | — | ||
| Q4 25 | $10.9B | $24.6B | ||
| Q3 25 | $10.4B | $24.0B | ||
| Q2 25 | $10.3B | $23.7B | ||
| Q1 25 | $9.6B | $21.9B | ||
| Q4 24 | $10.0B | $22.5B | ||
| Q3 24 | $9.7B | $22.5B | ||
| Q2 24 | $9.8B | $22.4B |
| Q1 26 | $3.0B | — | ||
| Q4 25 | $2.5B | $5.1B | ||
| Q3 25 | $2.9B | $5.2B | ||
| Q2 25 | $2.9B | $5.5B | ||
| Q1 25 | $2.6B | $11.0B | ||
| Q4 24 | $2.2B | $3.4B | ||
| Q3 24 | $2.5B | $2.7B | ||
| Q2 24 | $3.0B | $4.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 67.6% | ||
| Q3 25 | — | 69.6% | ||
| Q2 25 | — | 67.9% | ||
| Q1 25 | — | 66.4% | ||
| Q4 24 | — | 68.3% | ||
| Q3 24 | — | 69.0% | ||
| Q2 24 | — | 69.4% |
| Q1 26 | — | — | ||
| Q4 25 | 28.2% | 20.2% | ||
| Q3 25 | 36.7% | 31.2% | ||
| Q2 25 | 34.4% | 27.3% | ||
| Q1 25 | 34.6% | 62.3% | ||
| Q4 24 | 27.7% | 17.3% | ||
| Q3 24 | 33.0% | 14.9% | ||
| Q2 24 | 38.6% | 25.6% |
| Q1 26 | 15.7% | — | ||
| Q4 25 | 22.5% | 20.8% | ||
| Q3 25 | 27.9% | 21.5% | ||
| Q2 25 | 28.0% | 23.3% | ||
| Q1 25 | 26.8% | 50.2% | ||
| Q4 24 | 21.8% | 15.2% | ||
| Q3 24 | 25.8% | 12.0% | ||
| Q2 24 | 30.7% | 20.9% |
| Q1 26 | $4.28 | — | ||
| Q4 25 | $3.52 | $2.08 | ||
| Q3 25 | $4.14 | $2.12 | ||
| Q2 25 | $4.08 | $2.29 | ||
| Q1 25 | $3.64 | $4.54 | ||
| Q4 24 | $3.04 | $1.41 | ||
| Q3 24 | $3.49 | $1.11 | ||
| Q2 24 | $4.15 | $1.93 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $20.1B |
| Total DebtLower is stronger | $60.4M | $41.4B |
| Stockholders' EquityBook value | $34.0M | $81.5B |
| Total Assets | $308.9M | $199.2B |
| Debt / EquityLower = less leverage | 1.78× | 0.51× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $742.0M | $20.1B | ||
| Q3 25 | $1.3B | $18.6B | ||
| Q2 25 | $197.0M | $18.9B | ||
| Q1 25 | $261.0M | $38.8B | ||
| Q4 24 | $221.0M | $24.5B | ||
| Q3 24 | $120.0M | $20.3B | ||
| Q2 24 | $188.0M | $25.5B |
| Q1 26 | $60.4M | — | ||
| Q4 25 | $56.4B | $41.4B | ||
| Q3 25 | $57.8B | — | ||
| Q2 25 | $58.2B | — | ||
| Q1 25 | $51.2B | — | ||
| Q4 24 | $49.7B | $32.4B | ||
| Q3 24 | $53.5B | — | ||
| Q2 24 | $51.5B | — |
| Q1 26 | $34.0M | — | ||
| Q4 25 | $33.5B | $81.5B | ||
| Q3 25 | $32.4B | $79.3B | ||
| Q2 25 | $32.3B | $78.5B | ||
| Q1 25 | $31.2B | $78.1B | ||
| Q4 24 | $30.3B | $71.5B | ||
| Q3 24 | $29.7B | $70.2B | ||
| Q2 24 | $29.5B | $71.5B |
| Q1 26 | $308.9M | — | ||
| Q4 25 | $300.1B | $199.2B | ||
| Q3 25 | $297.6B | $192.8B | ||
| Q2 25 | $295.6B | $193.4B | ||
| Q1 25 | $282.2B | $193.7B | ||
| Q4 24 | $271.5B | $180.1B | ||
| Q3 24 | $271.0B | $178.3B | ||
| Q2 24 | $272.2B | $181.1B |
| Q1 26 | 1.78× | — | ||
| Q4 25 | 1.68× | 0.51× | ||
| Q3 25 | 1.78× | — | ||
| Q2 25 | 1.80× | — | ||
| Q1 25 | 1.64× | — | ||
| Q4 24 | 1.64× | 0.45× | ||
| Q3 24 | 1.80× | — | ||
| Q2 24 | 1.74× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $7.3B |
| Free Cash FlowOCF − Capex | — | $5.5B |
| FCF MarginFCF / Revenue | — | 22.3% |
| Capex IntensityCapex / Revenue | — | 7.5% |
| Cash ConversionOCF / Net Profit | — | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | — | $19.7B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $3.1B | $7.3B | ||
| Q3 25 | $6.2B | $9.2B | ||
| Q2 25 | $4.4B | $3.9B | ||
| Q1 25 | $4.8B | $4.2B | ||
| Q4 24 | $5.8B | $7.0B | ||
| Q3 24 | $-1.8B | $8.0B | ||
| Q2 24 | $4.5B | $5.6B |
| Q1 26 | — | — | ||
| Q4 25 | $2.3B | $5.5B | ||
| Q3 25 | $5.6B | $8.0B | ||
| Q2 25 | $3.7B | $2.8B | ||
| Q1 25 | $4.3B | $3.4B | ||
| Q4 24 | $5.3B | $5.4B | ||
| Q3 24 | $-2.3B | $7.0B | ||
| Q2 24 | $4.0B | $4.7B |
| Q1 26 | — | — | ||
| Q4 25 | 21.4% | 22.3% | ||
| Q3 25 | 53.6% | 33.4% | ||
| Q2 25 | 36.3% | 11.9% | ||
| Q1 25 | 45.0% | 15.4% | ||
| Q4 24 | 53.1% | 23.8% | ||
| Q3 24 | -23.3% | 31.0% | ||
| Q2 24 | 40.4% | 20.7% |
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | 7.5% | ||
| Q3 25 | 6.3% | 4.8% | ||
| Q2 25 | 6.0% | 4.4% | ||
| Q1 25 | 4.5% | 3.6% | ||
| Q4 24 | 5.0% | 7.2% | ||
| Q3 24 | 4.7% | 4.6% | ||
| Q2 24 | 5.8% | 4.3% |
| Q1 26 | — | — | ||
| Q4 25 | 1.25× | 1.43× | ||
| Q3 25 | 2.15× | 1.78× | ||
| Q2 25 | 1.51× | 0.70× | ||
| Q1 25 | 1.84× | 0.38× | ||
| Q4 24 | 2.66× | 2.04× | ||
| Q3 24 | -0.72× | 2.97× | ||
| Q2 24 | 1.50× | 1.20× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXP
Segment breakdown not available.
JNJ
| Other | $14.2B | 58% |
| Immunology | $2.5B | 10% |
| Orthopaedics | $1.5B | 6% |
| Neuroscience | $1.4B | 6% |
| Cardiovascular | $1.4B | 6% |
| Surgery | $1.1B | 4% |
| Pulmonary Hypertension | $865.0M | 4% |
| Cardiovascular Metabolism Other | $794.0M | 3% |
| Vision | $531.0M | 2% |
| Infectious Diseases | $303.0M | 1% |
